

**BLACKHAWK'S MINDBIO ANNOUNCES PHASE 2A/B
CLINICAL TRIALS MICRODOSING LSD IN MAJOR DEPRESSIVE DISORDER
SUBMITTED FOR ETHICS & REGULATORY APPROVAL**

- **Submission of Phase 2A/B clinical trials for Ethics & Regulatory Approval**
- **Completion of Safety Analysis of Phase 1 Clinical Trial Data for Lysergic Acid Diethylamide (LSD) for Microdosing Applications**

Vancouver, British Columbia – September 28, 2022 – Blackhawk Growth Corp. (CSE:BLR; Frankfurt:0JJ) (the “**Company**” or “**Blackhawk**”) subsidiary MindBio Therapeutics (“MindBio”) announces Phase 2a/b Clinical Trials have been submitted for ethics and regulatory approval.

MindBio is working exclusively in psychedelic microdosing clinical trials with scientific collaborators at the University of Auckland to develop intellectual property and novel microdosing treatments for mental health conditions that can be commercialized and used to treat patients in the primary health care system.

The submission for ethics approval for Phase 2A/B clinical trials microdosing LSD in patients with Major Depressive Disorder comes after the successful April 2022 completion of Phase 1 clinical trials microdosing LSD in 80 healthy participants and NZ\$1.44 million funding granted from the Health Research Council of New Zealand for the Phase 2 trials. Safety data from Phase 1 Trials will be presented at [#WonderlandMiami](#) convention, the world’s biggest psychedelics event on 4 November 2022.

In the US alone, in 2020 according to the National Institute of Mental Health, an estimated 21.0 million adults had at least one major depressive episode and 41.6% of those people sought some form of treatment. MindBio is developing a microdosing treatment protocol to address this treatment challenge in depression.

“MindBio is leading the way in psychedelic microdosing clinical trials. The MindBio team is progressing towards Phase 2A/B Clinical Trials and we are excited about the potential of microdosing treatments to assist patients suffering from Major Depressive Disorder.” said Frederick Pels, CEO of Blackhawk.

MindBio has been nominated in the industry awards for Company of the Year and LSD Company of the Year and Co-Founder Justin Hanka nominated for Entrepreneur of the Year and Innovator of the Year.

Investors can vote for MindBio and Co-Founder Justin Hanka [here](#)

About Blackhawk Growth

Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

About the University of Auckland

The University of Auckland is Aotearoa New Zealand’s leading university, ranked 87th in the world in the QS World Rankings 2022 and sixth in the Times Higher Education University Impact Rankings that measure performance against the Sustainable Development Goals. High-quality research across the full range of disciplines, represented by its eight faculties and two Large-Scale Research Institutes, ensures its place among the leading international research universities.